Group 1 - The company has established a remote diagnostic network covering over 2,700 hospitals nationwide, leveraging the "China Digital Pathology Remote Diagnosis and Quality Control Platform" from the National Health Commission [2][3] - The company has accumulated over 2 million typical case digital pathology slice data [2][3] - The company is collaborating with domestic enterprises to develop a "Pathology Auxiliary Diagnosis System" aimed at addressing the shortage of pathology doctors and limited diagnostic experience in grassroots hospitals [2][3]

证券日报网讯 1月23日，麦克奥迪在互动平台回答投资者提问时表示，公司的医疗产品主要包括细胞 DNA倍体分析系统、结核杆菌自动筛查系统、疟原虫自动诊断系统及免疫组化分析系统。公司联合国 内企业共同开发"病理辅助诊断系统"，希望通过辅助系统逐步解决基层医院病理医生资源不足、诊断经 验有限的痛点。 （文章来源：证券日报） ...

证券日报网讯1月23日，麦克奥迪（300341）在互动平台回答投资者提问时表示，公司智能电气业务专 注于环氧绝缘件的研发与制造，电压等级涵盖10kV至1100kV，是全球少数具备全电压等级制造能力的 制造商。公司将把握产业升级发展历史机遇，积极响应电力系统建设需求，聚焦中压、高压、绝缘拉杆 等产品，为下游开关柜企业提供更安全、更环保的产品，为新能源发展开发更适配的产品。 ...

Core Viewpoint - The company is actively developing AI medical solutions to address challenges in pathology diagnosis, particularly in resource-limited settings [1] Group 1: Company Initiatives - The company's medical products include cell DNA ploidy analysis systems, automated screening systems for tuberculosis, automated diagnostic systems for malaria, and immunohistochemistry analysis systems [1] - The company is collaborating with domestic enterprises to develop a "pathology auxiliary diagnosis system" aimed at alleviating the shortage of pathology doctors and limited diagnostic experience in grassroots hospitals [1]

Core Viewpoint - The medical device sector experienced a rise of 0.54% on January 21, with N Aisheren leading the gains, while the Shanghai Composite Index increased by 0.08% and the Shenzhen Component Index rose by 0.7% [1] Group 1: Stock Performance - N Aisheren (code: 920050) closed at 44.04, with a remarkable increase of 175.59% and a trading volume of 141,600 shares [1] - Tianzhihang (code: 688277) saw a rise of 12.38%, closing at 23.88 with a trading volume of 376,500 shares [1] - Xishan Technology (code: 688576) increased by 11.18%, closing at 76.80 with a trading volume of 34,000 shares [1] - Kangzhong Medical (code: 688607) rose by 10.91%, closing at 59.67 with a trading volume of 76,200 shares [1] - Shuoshi Biological (code: 6658889) increased by 9.74%, closing at 84.84 with a trading volume of 70,300 shares [1] Group 2: Capital Flow - The medical device sector saw a net inflow of 300 million yuan from institutional investors, while retail investors experienced a net outflow of 430 million yuan [2] - Major stocks like Sainuo Medical (code: 688108) had a net inflow of 69.18 million yuan from institutional investors, but a net outflow of 44.76 million yuan from retail investors [3] - LePu Medical (code: 300003) had a net inflow of 48.54 million yuan from institutional investors, with a slight net inflow of 0.52 million yuan from retail investors [3]

证券日报网讯1月16日，麦克奥迪（300341）在互动平台回答投资者提问时表示，公司的医疗产品主要 包括细胞DNA倍体分析系统、结核杆菌自动筛查系统、疟原虫自动诊断系统及免疫组化分析系统。公 司联合国内企业共同开发"病理辅助诊断系统"，希望通过辅助系统逐步解决基层医院病理医生资源不 足、诊断经验有限的痛点。公司目前没有与蚂蚁阿福存在合作关系。 ...

Core Insights - The company has established one of the largest pathology databases in China, accumulating over 12.6 million DNA diploid cervical screening samples, more than 400,000 other tissue DNA diploid samples, and 1 million digital pathology slices of typical cases [2] Group 1: Digital Medical Business - The company relies on its digital medical business to build a substantial database for pathology, enhancing its capabilities in the healthcare sector [2] Group 2: Optical Technology - The company has over 30 years of experience in the optical field, showcasing strong research and development capabilities that support its expansion in industrial inspection [2]

证券日报网讯1月16日，麦克奥迪（300341）在互动平台回答投资者提问时表示，公司将根据《上市公 司重大资产重组管理办法》等要求，严格履行信息披露义务和相应决策程序。 ...

证券日报网讯1月16日，麦克奥迪（300341）在互动平台回答投资者提问时表示，公司将根据法律法规 严格履行信息披露义务。 ...

Core Insights - The biopharmaceutical industry in China is a strategic emerging industry, crucial for public health, technological innovation, and enhancing national pharmaceutical autonomy. The market size is projected to grow from CNY 4,210 billion in 2022 to CNY 8,000 billion by 2028, with an annual growth rate stabilizing between 10%-12% [1][2][23]. Industry Overview - In 2020, the biopharmaceutical market in China was valued at CNY 3,457 billion, increasing to CNY 4,100 billion in 2021, representing an 18.6% year-on-year growth. However, growth slowed to 2.68% in 2022, with a slight increase to CNY 4,210 billion [1][2]. - The industry is segmented into upstream (raw materials and medical devices), midstream (drug synthesis and production), and downstream (drug distribution). Biopharmaceuticals and chemical drugs have higher profit margins, with biopharmaceutical companies reporting gross margins of 80%-86% [2][4]. Xiamen Biopharmaceutical Industry - Xiamen is a key hub for biopharmaceutical industry development, recognized as a national strategic emerging industry cluster. The local government has implemented various supportive policies since 2016, focusing on innovation and industrialization [6][9]. - The industrial output value of Xiamen's biopharmaceutical sector reached CNY 1,045.87 billion in 2022, with a slight decline to CNY 847 billion in 2023, and is projected to stabilize around CNY 840 billion in 2024 [17][18]. Policy Environment - Xiamen's government has introduced multiple measures to support the biopharmaceutical industry, including financial incentives for R&D and commercialization, with significant rewards for new drug development and medical device innovation [9][26]. - The city aims to establish a CNY 100 billion venture capital fund and enhance the entire process from R&D to clinical application by 2025 [23][26]. Future Outlook - By 2025, Xiamen plans to significantly increase the number of registered biopharmaceutical companies, with projections indicating over 2,200 registered firms, marking a notable rise from previous years [18]. - The city aims to develop a CNY 700 billion biopharmaceutical industry chain, supported by specialized parks and a focus on various sub-sectors, including biopharmaceuticals and medical devices [23][26].